Master of Research in Biomedical Sciences with a specialisation in Integrative Mammalian Biology (IMB) [Systems]

我们提交的标题下'在体内技能'。然而，我们将把体内训练与“系统生物学”训练结合起来。这些奖学金还将培养制药行业需求的技能能力（见下文和“支持案例”）。整合哺乳动物生物学（IMB）体内技能与系统生物学的整合是一种新的研究方法，因此，很少有学生在这两个学科都受过训练，因此无法从事涉及系统生物学和体内技术的博士课程或研究职业。该硕士培训将提供新一代拥有这些技能的年轻科学家，因此将具有独特的地位，可以进行相关的博士学位或获得越来越需要具有这些不同技能的研究人员的工业研究职位。阿斯利康和辉瑞的支持信附后。学生将参加在生物医学科学研究的完善的硕士。详见随附课程文件。格拉斯哥/斯特拉斯克莱德大学是四个“中心”之一，被授予约300万美元，以建立综合哺乳动物生物学（IMB）研究的能力（由BBSRC，MRC，辉瑞，阿斯利康葛兰素史克，SHEFC，HEFC，英国药理学学会资助; M麦克莱恩教授是PI和该倡议的主任）。学生将参加生物医学科学研究硕士课程，该课程是IMB计划的一部分，是为满足希望学习体内技能的学生的需求而量身定制的。http://www.gla.ac.uk/faculties/fbls/gs/masterscourses/mresinbiomedicalsciencesintegrativemammalianbiology/他们将开展两个项目，将体内哺乳动物生物学与系统生物学相结合，这些项目将由在研究和培训方面表现出色的资深工作人员监督.附件“可能的项目”中仅列举了几个项目的例子。他们还将参加由辉瑞公司的科学家提供的为期半天的研讨会或讲习班，为他们提供系统生物学在药物开发研究中的应用知识（见所附的支持信）。他们将参加两个独特的年度IMB资助的暑期学校之一，旨在教育整个英国的学生在基本的体内技能（见“具体技能”下的更多细节。我们设想，这个硕士课程将“发展”与科学的进步和需求。例如，将根据行业发展情况就课程设计咨询辉瑞公司（见支持信）。注意事项：选择用于此应用程序的工作人员来自监督生物医学科学研究硕士项目的工作人员（综合哺乳动物生物学（BS）专业）以及为BBSRC/EPSRC细胞和蛋白质组学技术博士培训中心（CPT）做出贡献的系统生物学家。在“课程历史”下提供的数据包括注册这两门课程的学生，这两门课程的课程信息文件作为附件提交。为了清楚起见，参考“课程历史”：2006年，28名学生开始在BS，7名在CPT; 2007年，30名开始在BS，7名在CPT; 2008年，36名开始在BS，5名在CPT。

We are submitting under the heading 'in vivo skills'. However we will integrate the in vivo training with training in 'systems biology'. These studentships will also build capacity in skills for which there is demand within the pharmaceutical industry sector (see below and 'Case for Support'). The integration of integrative mammalian biology (IMB) in vivo skills with systems biology is a novel approach to research and as such, very few students are trained in both disciplines and so are ill-equip to embark on a PhD programme or research career that involves both systems biology and in vivo techniques. This Masters training will provide a new generation of young scientists that have these skills and will therefore be uniquely placed to either carry out a related PhD or obtain industrial research placements that will increasingly require researchers with these diverse skills. Letters of support from AstraZeneca and Pfizer are attached. Students will enrol in the well established Master of Research in Biomedical Sciences. See attached course document for details. Glasgow/Strathclyde Universities were one of four 'centres' to be awarded circa ¿ú3m to build capacity in Integrative Mammalian Biology (IMB) studies (Funded by BBSRC, MRC, Pfizer, AstraZeneca GlaxoSmithKline, SHEFC, HEFC, British Pharmacological Society; Prof M MacLean is PI and director of this initiative). The students will take the Master of Research in Biomedical Sciences with the specialisation in IMB which was set up as part of the IMB initiative and is tailor-made to meet the needs of students wishing to learn in vivo skills. http://www.gla.ac.uk/faculties/fbls/gs/masterscourses/mresinbiomedicalsciencesintegrativemammalianbiology/ They will carry out two projects that will integrate in vivo mammalian biology with systems biology and these will be supervised by established staff selected for excellence in research and training. Examples of just a few projects are given in the attachment 'Potential projects'. They will also attend a half-day seminar or workshop which will be provided by scientists from Pfizer to provide them with knowledge of the application of systems biology to drug development research (see attached letter of support). They will attend one of the two unique annual IMB-funded summer schools designed to educate students throughout the UK in basic in vivo skills (see under 'specific skills' for more details. We envisage that this Masters course will 'evolve' with advances in science and with demand. For example Pfizer will be consulted about the design of the course in line with developments in industry (see letter of support). Note: The staff selected for this application have been drawn from staff who supervise projects for the Master of Research in Biomedical Sciences (specialisation in Integrative Mammalian Biology (BS)) as well as systems biologists contributing to the BBSRC/EPSRC Doctoral Training Centre in Cell & Proteomic Technologies (CPT). The data provided under 'Course History' includes students enrolling into both these courses and the Course Information Documents for both courses are submitted as attachments. For clarity, in reference to 'Course History': In 2006 28 students started in BS, 7 in CPT; in 2007 30 started in BS, 7 in CPT; in 2008 36 started in BS, 5 in CPT.